Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

A copolymer includes a main hydrocarbon chain and side groups including carboxylic groups and polyoxyalkylate groups. The copolymer further includes gem-bisphosphonate groups. The copolymer can be included in an admixture for suspensions of mineral particles and in a composition of mineral particles. The copolymer can also be used for fluidifying and maintaining fluid, suspensions of mineral particles and for reducing the sensitivity of hydraulic compositions to clays and alkaline sulfates.

The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90 C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95 C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3). The crystalline hemihydrate form F of sodium neridronate, particularly stable, may be employed in the preparation of solid oral pharmaceutical forms for use in the treatment of musculoskeletal and calcium metabolism disorders.

The present disclosure provides a pressure-reducing and injection-enhancing anti-scaling agent for low-permeability water-injection wells and a preparation method thereof. The anti-scaling agent is prepared from starting materials comprising: 10 to 12 parts of non-ionic surfactant(s), 18 to 20 parts of hexasodium triethylenetetramine-N,N,N,N,N,N-hexaacetate, 5 to 8 parts of anionic surfactant(s), 6 to 8 parts of an organic phosphonic acid-carboxylic acid scale inhibitor, 2 to 5 parts of a dispersant, 15 to 18 parts of a diluent, 8 to 10 parts of an organic amine salt, and 30 to 36 parts of water. The pressure-reducing and injection-enhancing agent according to the present disclosure is characterized by having multiple functions in one agent. When used in an amount being 0.5% of the water injected to a water injection well, it shows excellent anti-swelling property, shrinking property, anti-corrosive property, and calcium sulfate and barium (strontium) sulfate scale resistance.

Downhole tools, methods, and systems related thereto. An example downhole tool includes a body comprising a degradable core and a chelating agent or a chelating agent/scale inhibitor mixture integrated therein. The chelating agent and scale inhibitors help to direct and control the degradation of the degradable core.

The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy

The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy.

The invention provides a radically polymerizable compound wherein an acid group is joined via a spacer group to a polyethyleneimine group. The polyethyleneimine group has at least one radically polymerizable group in the side chain and/or terminally. The invention relates further to a process for preparing such compounds by cationic polymerization of oxazolines, to the use of such compounds as constituents of a dental material, and to a dental material comprising the compounds of the invention.

The present invention relates to crystallizates of the pure aminoalkylenephosphonic acid DTPMP in three crystal polymorphs and to a process for obtaining solid crystalline DTPMP by a preferably one-stage crystallization from an aqueous product mixture comprising DTPMP, wherein the process comprises the following process steps: (a) introducing seed crystals comprising DTPMP into an aqueous crude product comprising DTPMP with a total proportion in the range from 10 to 65 percent by mass up to a suspension density in the range from 1% to 25%; (b) introducing kinetic energy into the aqueous crude product to precipitate a crystallizate containing DTPMP as pure acid with a total content of at least 75% by mass; and (c) removing the crystallizate formed from the aqueous crude product by sedimentation and/or filtration, such that DTPMP is obtained as a solid end product in the form of a crystallizate.

A compound or a polymer is claimed. A first formula can be ##STR00001##
wherein X is H, CH.sub.3, CN, phenyl, substituted phenyl, (CH.sub.2).sub.mZ, or phenyl(CH.sub.2).sub.mZ; T is O, N, S or NH; m equals 1 to 20; n equals 1-100; and Z is CN, NH.sub.2, Thiol, OH, or CO.sub.2H. The second formula is: ##STR00002##
wherein X is H, CH.sub.3, CN, phenyl, substituted phenyl, (CH.sub.2).sub.mZ, or phenyl(CH.sub.2).sub.mZ; and Z is CN, NH.sub.2, Thiol, OH, or CO.sub.2H. The third formula is ##STR00003##
wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently: H, CH.sub.3, OH, or a halogen.